- Home
- O vs TAK Comparison
O vs TAK Comparison
Compare O & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | O | TAK |
|---|---|---|
| Founded | 1969 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.1B | 56.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | O | TAK |
|---|---|---|
| Price | $64.94 | $18.17 |
| Analyst Decision | Hold | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $64.83 | N/A |
| AVG Volume (30 Days) | ★ 6.1M | 2.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.99% | 2.95% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.18 | $0.04 |
| Revenue Next Year | $6.70 | $0.92 |
| P/E Ratio | $60.73 | ★ $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $50.71 | $12.99 |
| 52 Week High | $67.94 | $18.82 |
Technical Indicators
Market Signals| Indicator | O | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 53.27 | 55.14 |
| Support Level | $55.96 | $17.51 |
| Resistance Level | $67.94 | $18.82 |
| Average True Range (ATR) | 0.97 | 0.24 |
| MACD | -0.41 | -0.15 |
| Stochastic Oscillator | 24.46 | 51.12 |
Price Performance
Historical ComparisonAbout O Realty Income Corporation
Realty Income owns roughly 15,600 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, gaming, office, manufacturing, and distribution properties, which make up roughly 20% of revenue.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.